FINNENCE ▪ THE WIRE FILE
THE WIRE · № 73456
News■ Unclear/unknown
Quince relaunches as IRulya, going all in on lung disease after Hail Mary merger
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-10-09 15:05 UTC
LAST UPDATE2026-10-09 15:05 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A reverse merger into a lung-disease focus is a strategic pivot whose value depends on pipeline execution, not the rebranding.
Rebranding alone won't validate the new strategy
CATALYST TO WATCH
Clinical data or financing announcements
MAIN RISK
Thin pipeline could fail to attract capital
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
TRex prices IPO at bottom of range as Retension makes its public debut2026-10-09 17:48 UTC
TRex prices IPO at bottom of range as Retension makes its public debut2026-10-09 17:48 UTC
→CORRELATIONshares Healthcare
TRrexBio’s IPO Bags $116M to Bring the Immune System Back Into Balance2026-10-09 18:28 UTC
TRrexBio’s IPO Bags $116M to Bring the Immune System Back Into Balance2026-10-09 18:28 UTC
→CORRELATIONshares Healthcare
Cardiotonic Agents Market to Reach USD 10,337.3 Million by 20342026-10-09 18:39 UTC
Cardiotonic Agents Market to Reach USD 10,337.3 Million by 20342026-10-09 18:39 UTC
→CORRELATIONshares Healthcare
VVVV IPO News - Cavity treatment provider vVardis files for an estimated $200 million US IPO2026-10-09 18:12 UTC
VVVV IPO News - Cavity treatment provider vVardis files for an estimated $200 million US IPO2026-10-09 18:12 UTC
←CORRELATIONshares Healthcare
TRex rakes in $117M IPO, while Retension reveals $45M listing2026-10-09 08:29 UTC
TRex rakes in $117M IPO, while Retension reveals $45M listing2026-10-09 08:29 UTC
←CORRELATIONshares Healthcare
Phase 3 results posted: A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer — Hoffmann-La Roche2026-10-09 12:00 UTC
Phase 3 results posted: A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer — Hoffmann-La Roche2026-10-09 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.